---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-23-000020"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T13:12:15.677768+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics reports Q4 2022 net loss of $29.7M; cash runway into Q3 2025

## Summary
- Net loss of $29.7M for Q4 2022 vs $6.9M in Q4 2021; full year net loss $104.7M vs $58.7M.
- No revenue in 2022; 2021 revenue of $20.1M from Hansoh license agreement.
- R&D expenses $24.9M in Q4 2022, up from $18.8M; driven by Phase 2 trials of KER-050.
- Cash and equivalents $279.0M at Dec 31, 2022; with ATM proceeds, funds operations into Q3 2025.
- Anticipated 2023 milestones: complete MDS trial enrollment, report additional data for KER-050, KER-047, KER-012.

## SEC filing metadata
- accession: 0001664710-23-000020
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/0001664710-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/kros-20230303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-23-000020
- JSON: https://secwatch.observer/filing/0001664710-23-000020.json
- Plain text: https://secwatch.observer/filing/0001664710-23-000020.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Net income: net loss of $29.7 million for the fourth quarter and $104.7 million for the year ended December 31, 2022
  - Result: reported results
  source text: Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000020/0001664710-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.